What's the most recent regulatory action in Escherichia coli urinary tract infection?

Most recent: Monurol — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/escherichia-coli-urinary-tract-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Escherichia coli urinary tract infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Escherichia coli urinary tract infection (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Escherichia coli urinary tract infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Fetroja	CEFIDEROCOL	Shionogi	Cephalosporin Antibacterial		2019-01-01
Recarbrio	RELEBACTAM	Merck & Co.	Renal Dehydropeptidase Inhibitor [EPC]		2019-01-01
Vabomere	VABORBACTAM	Rempex Pharms Inc	beta Lactamase Inhibitor [EPC]		2017-01-01
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Invanz	ERTAPENEM	Merck & Co.	Penem Antibacterial		2001-01-01
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Cystadane	BETAINE	Recordati	Methylating Agent [EPC]		1996-01-01
Maxipime	CEFEPIME	Baxter	Cephalosporin Antibacterial		1996-01-01
Maxipime	Cefepime Hydrochloride	Baxter	Cephalosporin	Bacterial cell wall peptidoglycan	1996-01-01
Monurol	FOSFOMYCIN	Zambon Spa	fosfomycin		1996-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-04-09 — Monurol · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 17 drugs in Escherichia coli urinary tract infection
Bristol-Myers Squibb · 4 drugs in Escherichia coli urinary tract infection
Baxter · 2 drugs in Escherichia coli urinary tract infection
Pfizer · 2 drugs in Escherichia coli urinary tract infection
GSK · 2 drugs in Escherichia coli urinary tract infection
Pai Holdings Pharm · 2 drugs in Escherichia coli urinary tract infection
Shionogi · 2 drugs in Escherichia coli urinary tract infection
Merck & Co. · 2 drugs in Escherichia coli urinary tract infection
Bayer AG · 1 drug in Escherichia coli urinary tract infection
Allergan · 1 drug in Escherichia coli urinary tract infection
Generic (originally Beecham/GSK) · 1 drug in Escherichia coli urinary tract infection
Dr Reddys Labs Sa · 1 drug in Escherichia coli urinary tract infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Escherichia coli urinary tract infection:

Cite this brief

Drug Landscape (2026). Escherichia coli urinary tract infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/escherichia-coli-urinary-tract-infection. Accessed 2026-06-10.

Escherichia coli urinary tract infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing